Immune System News and Research

RSS

Nuvo Research reports net income in fourth-quarter, driven by FDA approval of Pennsaid

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the year and the fourth quarter ended December 31, 2009.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

Emerging concepts from gene regulation studies in immune cells

The seventh meeting in the “Emergence and Convergence” series jointly organized by La Fondation IPSEN and Nature brings together today in San Antonio (Texas, USA) leading experts to discuss concepts emerging from gene regulation studies in immune cells that have led to insights into the initiation and maintenance of epigenetic chromatin marks necessary for proper differentiation and function of these cells in the immune system.

19 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

Gentel Biosciences launches integrated Proteomics Multi-System

Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.

19 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

V-Day to host three benefit productions of The Vagina Monologues as part of global violence against women

Ottawa V-Day, part of a global campaign to end violence against women and girls, will host three benefit productions of The Vagina Monologues on Friday, February 26 and Saturday, February 27 at the National Gallery of Canada.

18 Feb 2010

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe.

18 Feb 2010

Healthy immune response depends on TRPV2 protein

If bad bacteria lurk in your system, chances are they will bump into the immune system's protective cells whose job is gobbling germs.

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

A new Cochrane review did not find clear evidence that taking zinc supplements reduces the occurrence of middle ear infections or otitis media in healthy children.

18 Feb 2010

Eleven Biotherapeutics announces completion of $35M Series A funding

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company’s portfolio of engineered proteins through clinical proof of concept.

17 Feb 2010

Research on mosquito genes could be used for disease control measures

By unraveling the mysteries that exist within the molecular composition of mosquitoes, a team of Kansas State University researchers is trying to discover how the insects survive a parasite that causes malaria in humans.

17 Feb 2010

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).

17 Feb 2010

International Stem Cell's human cornea technology: Clinical-commercial opportunities in Asia and Europe

International Stem Cell Corporation, announced today that multiple international meetings taking place between ISCO’s executive management and researchers and clinicians from commercial entities in both Asia and Europe revealed significant clinical-commercial opportunities for the company’s stem cell-derived human cornea technology in those regions.

17 Feb 2010

Researchers use new strategy to develop cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.

17 Feb 2010

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

Scientists battling malaria have earned a major victory. According to a Nature Genetics study, an international group of researchers has used genomics to decode the blueprint of Plasmodium falciparum - a strain of malaria most resistant to drugs that causes the most deaths around the world.

17 Feb 2010

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010.

17 Feb 2010

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Immune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, today announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company’s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are all participating. The round will be kept open until mid-2010 for new potential investors to invest.

17 Feb 2010

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.

17 Feb 2010

Immune System News and Research

Nuvo Research reports net income in fourth-quarter, driven by FDA approval of Pennsaid

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Emerging concepts from gene regulation studies in immune cells

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

Gentel Biosciences launches integrated Proteomics Multi-System

Rituxan, intended for patients with CLL receives FDA approval

V-Day to host three benefit productions of The Vagina Monologues as part of global violence against women

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

Healthy immune response depends on TRPV2 protein

Viral infection can suppress immune response to secondary bacterial infection

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

Eleven Biotherapeutics announces completion of $35M Series A funding

Research on mosquito genes could be used for disease control measures

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

International Stem Cell's human cornea technology: Clinical-commercial opportunities in Asia and Europe

Researchers use new strategy to develop cancer vaccines

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News